Bonus BioGroup Ltd. (BBIXF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -29.79 Million ILS | 19.59% |
| 2022 | -37.04 Million ILS | 42.77% |
| 2021 | -64.73 Million ILS | -232.93% |
| 2020 | -19.44 Million ILS | 7.01% |
| 2019 | -20.9 Million ILS | -13.33% |
| 2018 | -18.45 Million ILS | 8.35% |
| 2017 | -20.13 Million ILS | -26.1% |
| 2016 | -15.96 Million ILS | -19.14% |
| 2015 | -13.39 Million ILS | -19.84% |
| 2014 | -11.18 Million ILS | -15.53% |
| 2013 | -9.67 Million ILS | 46.13% |
| 2012 | -17.96 Million ILS | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -7.21 Million ILS | 12.4% |
| 2024 Q1 | -8.23 Million ILS | -20.58% |
| 2023 Q1 | -8.18 Million ILS | 17.64% |
| 2023 Q4 | -6.82 Million ILS | 8.91% |
| 2023 Q3 | -7.49 Million ILS | -2.94% |
| 2023 FY | -29.79 Million ILS | 19.59% |
| 2023 Q2 | -7.28 Million ILS | 11.07% |
| 2022 Q3 | -8.26 Million ILS | 10.69% |
| 2022 Q1 | -9.57 Million ILS | -0.08% |
| 2022 Q2 | -9.25 Million ILS | 3.34% |
| 2022 FY | -37.04 Million ILS | 42.77% |
| 2022 Q4 | -9.94 Million ILS | -20.21% |
| 2021 Q3 | -10.37 Million ILS | -29.25% |
| 2021 Q4 | -9.57 Million ILS | 7.75% |
| 2021 FY | -64.73 Million ILS | -232.93% |
| 2021 Q1 | -36.76 Million ILS | -520.04% |
| 2021 Q2 | -8.02 Million ILS | 78.16% |
| 2020 Q2 | -4.15 Million ILS | 17.74% |
| 2020 Q1 | -5.05 Million ILS | -10.36% |
| 2020 Q3 | -4.3 Million ILS | -3.71% |
| 2020 FY | -19.44 Million ILS | 7.01% |
| 2020 Q4 | -5.92 Million ILS | -37.6% |
| 2019 Q3 | -4.56 Million ILS | -8.18% |
| 2019 Q1 | -7.55 Million ILS | -49.43% |
| 2019 FY | -20.9 Million ILS | -13.33% |
| 2019 Q4 | -4.57 Million ILS | -0.35% |
| 2019 Q2 | -4.21 Million ILS | 44.2% |
| 2018 Q1 | -5.02 Million ILS | -36.63% |
| 2018 Q4 | -5.05 Million ILS | -14.7% |
| 2018 FY | -18.45 Million ILS | 8.35% |
| 2018 Q3 | -4.4 Million ILS | -11.37% |
| 2018 Q2 | -3.95 Million ILS | 21.28% |
| 2017 FY | -20.13 Million ILS | -26.1% |
| 2017 Q3 | -9.35 Million ILS | -160.84% |
| 2017 Q2 | -3.58 Million ILS | -2.02% |
| 2017 Q4 | -3.68 Million ILS | 60.65% |
| 2017 Q1 | -3.51 Million ILS | -6.81% |
| 2016 Q1 | -3.17 Million ILS | 27.69% |
| 2016 FY | -15.96 Million ILS | -19.14% |
| 2016 Q2 | -3.18 Million ILS | -0.19% |
| 2016 Q4 | -3.29 Million ILS | 47.87% |
| 2016 Q3 | -6.31 Million ILS | -98.21% |
| 2015 Q3 | -3.48 Million ILS | -19.08% |
| 2015 Q2 | -2.92 Million ILS | -12.59% |
| 2015 Q1 | -2.59 Million ILS | 9.89% |
| 2015 FY | -13.39 Million ILS | -19.84% |
| 2015 Q4 | -4.39 Million ILS | -26.22% |
| 2014 Q2 | -2.95 Million ILS | 7.42% |
| 2014 FY | -11.18 Million ILS | -15.53% |
| 2014 Q1 | -3.19 Million ILS | 2.14% |
| 2014 Q3 | -2.16 Million ILS | 26.72% |
| 2014 Q4 | -2.88 Million ILS | -32.99% |
| 2013 FY | -9.67 Million ILS | 46.13% |
| 2013 Q1 | -2.13 Million ILS | 0.0% |
| 2013 Q2 | -1.88 Million ILS | 11.64% |
| 2013 Q3 | -2.47 Million ILS | -31.4% |
| 2013 Q4 | -3.26 Million ILS | -31.99% |
| 2012 FY | -17.96 Million ILS | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | -17.84 Million USD | -66.919% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -490.546% |
| CSL Limited | 3.7 Billion USD | 100.805% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 136.395% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -4236.56% |
| BioStem Technologies, Inc. | -7.77 Million USD | -282.956% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -2271.815% |
| Qrons Inc. | -643.67 Thousand USD | -4528.098% |
| Nascent Biotech, Inc. | -2.22 Million USD | -1235.947% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 46.332% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -348.104% |
| Skye Bioscience, Inc. | -13.67 Million USD | -117.894% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -7070.037% |
| Rebus Holdings, Inc. | -664 Thousand USD | -4386.446% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -87.716% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -2130.74% |
| Genscript Biotech Corporation | -415.79 Million USD | 92.835% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -7546.893% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 58.502% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 706.127% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -11282.132% |
| SQZ Biotechnologies Company | -75.82 Million USD | 60.712% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -945.077% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -1839.391% |
| Mesoblast Limited | -84.14 Million USD | 64.598% |
| Marizyme, Inc. | -34.08 Million USD | 12.605% |
| Genus plc | 6.4 Million USD | 565.469% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 405.775% |
| Pharming Group N.V. | -4.87 Million USD | -510.508% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -1399.638% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -3098.48% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -256.766% |
| ContraFect Corporation | -56.88 Million USD | 47.635% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -554.046% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -2024.835% |
| IMV Inc. | -38.67 Million USD | 22.967% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -982.942% |
| MultiCell Technologies, Inc. | -722.81 USD | -4121315.033% |
| ONE Bio Corp. | 13.68 Million USD | 317.739% |
| Accustem Sciences Inc. | -3.74 Million USD | -695.159% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 49.5% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -6066.91% |
| Q BioMed Inc. | -3.44 Million USD | -764.577% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 941.525% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -1033.768% |
| Biomind Labs Inc. | -1 Million USD | -2850.665% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 45.809% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -926.799% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -1497.859% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -99359.135% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -1441.439% |
| GB Sciences, Inc. | -1.42 Million USD | -1997.136% |
| Alpha Cognition Inc. | -9.7 Million USD | -206.936% |
| HST Global, Inc. | -140.9 Thousand USD | -21041.604% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -2548.221% |
| Halberd Corporation | -75.05 Thousand USD | -39593.538% |
| Enzolytics Inc. | -2.14 Million USD | -1286.355% |
| Agentix Corp. | -1.37 Million USD | -2071.669% |
| Resverlogix Corp. | -12.74 Million USD | -133.665% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -840.26% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 92.991% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -2753.448% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -920.4% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -1786.213% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -774.895% |
| AVAX Technologies, Inc. | 6.69 Million USD | 545.1% |
| Zenith Capital Corp. | -8.94 Million USD | -233.11% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -170900.517% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -1113.285% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -17269.296% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -1385.966% |
| Kadimastem Ltd | -3.04 Million USD | -879.854% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -2927.276% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -16314.58% |
| LadRx Corporation | -3.82 Million USD | -679.103% |
| Cell Source, Inc. | -4.32 Million USD | -588.731% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -4236.56% |
| NovAccess Global Inc. | -2.46 Million USD | -1107.657% |
| Affymax, Inc. | -15.04 Million USD | -97.993% |
| Itoco Inc. | -919.14 Thousand USD | -3141.073% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -602.857% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -2562.198% |
| Mobile Lads Corp. | -554.55 Thousand USD | -5271.923% |
| CytoDyn Inc. | -18.05 Million USD | -64.968% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -118255.185% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -13436.11% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -5175.153% |
| SYBLEU INC | -149.18 Thousand USD | -19869.165% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -1540.129% |
| International Stem Cell Corporation | -663 Thousand USD | -4393.213% |
| Bioxytran, Inc. | -3.82 Million USD | -679.813% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -56491.945% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -146360.177% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 17.857% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -1741.162% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -3948.462% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -857.57% |
| Neutra Corp. | -229.48 Thousand USD | -12881.184% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -69.85% |
| PureTech Health plc | -146.19 Million USD | 79.624% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -38.615% |
| IXICO plc | -1.43 Million USD | -1973.069% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -213.876% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 75.543% |
| CSL Limited | 3.81 Billion USD | 100.781% |
| Cellectis S.A. | -108.85 Million USD | 72.634% |